Sava Technologies Ltd. is a London-based startup developing an innovative wearable biosensor platform using proprietary microsensor technology to detect molecules just under the skin in a painless, real-time, and affordable way. Starting with continuous glucose monitoring (CGM) for diabetes patients, it has demonstrated 10-day clinical evidence and aims for commercial availability in 2027, with plans to expand to multi-molecule biosensing for preventative and personalised healthcare.